LATEST UPDATES » Vol 25, No. 05, May 2020 – Surviving COVID-19: Personal Experience of Dr. J Richard Smith       » Open Source AI-Powered Tool by Tencent for COVID-19 Preliminary Self Evaluation       » COVID-19 and its Impact on a Global and Societal Scale       » Optimal Egg Consumption to Lower Risk of Cardiovascular Disease       » Cohort Analysis of Remdesivir as Antiviral Treatment for COVID-19       » Easing Strain on Healthcare Systems with COVID-19 Patient Management Platform      
Vol 24, No. 05, May 2020For e-subscribers (PDF)
Discovery of Protease Inhibitors hold Promise against COVID-19
Research team from at the Institute of Biological Chemistry at Academia Sinica screens viral protease inhibitor in a bid to develop a potential drug against COVID-19.

Amid the COVID-19 global pandemic, organizations and institutions across the world race to develop virus detecting kits, antiviral drugs, and vaccines, with hope to find a cure and stop the spread and infection of SAR-CoV-2.

In mid-February 2020, Academia Sinica (AS) President James Liao formed the COVID-19 Open Science Platform for scientists in Taiwan to have an avenue for publishing news on fighting the virus through their research. Together with long-term support from the Ministry of Science and Technology, a team led by Dr Liang Po-Huang, a Research Fellow at the Institute of Biological Chemistry of AS, as able to screen for inhibitors of viral protease.

The viral protease also known as 3C-like protease was screened from more than 100 possible inhibitors. Some of these inhibitors were proven effective against SAR-CoV-2 by Dr Lin Yi-Ling, Dr Jan Jia-Tsrong, and Professor Chang Sui-Yuen.

While animal and human experiments are still required for protease inhibitors turning into anti-COVID-19 drugs, finding potential inhibitors in such a short period demonstrates Taiwan’s capacity in dealing with the present global pandemic.

Presently, the research achievements are based on previous SARS research projects from 17 years ago, representing the culmination of continuous efforts over the years. compounds synthesized by former AS President Wong Chi-Huey and Professor Fang Jim-Min (Department of Chemistry, National Taiwan University); the SARS protease and inhibitors assaying method developed by Dr. Liang’s laboratory; and the protease-inhibitor complexes crystallized and structures solved by Academician Dr. Andrew H-J Wang’s laboratory.

Former doctoral students from those teams are contributing to current anti-COVID-19 research, including Dr. Kuo Chih-Jung (Dr. Liang’s former Ph.D. student, currently Associate Professor in the Department of Veterinary Medicine, National Chung Hsing University); Dr. Lee Cheng-Chung (Dr. Wang’s former Ph.D. student, now a senior scientist at AS’s Institute of Biological Chemistry), and Dr. Shie Jiun-Jie (Dr. Fang’s former Ph.D. student, currently Assistant Research Fellow at AS’s Institute of Chemistry).

Together they were able to produce the main protease of the SAR-CoV-2 virus – which is 12 amino acids different from the SARS virus – screened potential protease inhibitors, and obtain co-crystal structures.

Click here for the complete issue.

news Medtec China to return in September with integrated manufacturing resources for the entire high-end medical industry chain
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy